| Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule product candidates primarily to treat cancer. Substantially all of Co.'s existing effort is focused on its primary product candidate, rigosertib. Rigosertib is being tested in an intravenous formulation as a single agent, and an oral formulation in combination with azacitidine, in clinical trials for patients with higher-risk myelodysplastic syndromes. Briciclib, another of Co.'s product candidates, is a small molecule targeting an intracellular regulatory protein, Cyclin D1, which is often found at elevated levels in cancer cells. The ONTX YTD return is shown above.
The YTD Return on the ONTX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ONTX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ONTX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.